INTRODUCTION
Infectious hepatitis remains a key public health priority in industrialised countries. Acute infectious hepatitis (AIH) is characterised by an acute onset of discrete symptoms including fever, jaundice, abdominal pain, nausea and vomiting. Occasionally, the condition may progress to fulminant hepatic failure and the need for liver transplantation. Most childhood cases are caused by viruses, with hepatitis A virus (HAV) and hepatitis B virus (HBV) being the main culprits. Other viruses (eg, hepatitis E, Epstein-Barr, cytomegalovirus (CMV)) and nonviral infections (eg, toxoplasma, leptospirosis) may also cause AIH in children. Countries with routine childhood immunisation programmes, such as the USA, have observed significant reductions in the incidence of acute HAV (92%) and HBV (82%) infections, respectively, across all age groups. 1 The UK and Ireland do not routinely immunise against HAV and, while HBV vaccination is included in the Irish infant immunisation schedule, the UK has adopted a selective policy of vaccinating high-risk individuals only. 2 Little is known about the burden of childhood AIH in industrialised countries. In the UK, national surveillance systems are not set up to identify clinical syndromes such as AIH. Rates of laboratoryconfirmed infections due to specific pathogens are readily available, but are not accompanied with clinical or outcome data. Consequently, current knowledge of syndromic conditions such as AIH is very limited.
This study aimed to estimate the burden of childhood AIH in the UK and Ireland, with particular emphasis on the vaccine-preventable (HAV and HBV) aetiologies. Here, we report the overall and What is already known on this topic?
▸ Acute infectious hepatitis (AIH) is characterised by an acute onset of discrete symptoms including fever, jaundice, abdominal pain, nausea and vomiting. ▸ Most childhood cases are caused by viruses, especially hepatitis A virus and hepatitis B virus, although other viruses and non-viral infections may also be responsible. ▸ Little is known about the total burden, aetiology, clinical course, management or outcomes of childhood AIH in industrialised countries.
What this study adds?
▸ Sixty-nine cases were identified over the 13-month BPSU surveillance period (annual incidence, 0.52/100 000 children aged <14 years), and most recovered without complications ▸ The aetiology included hepatitis A (n=27, 39%) cases, hepatitis B (n=3, 4%) and 16 other viruses (23%), while 23 (33%) had no pathogen identified. ▸ Of the five children with acute hepatitis B infection, three developed liver failure and two required liver transplantation. pathogen-specific incidence, clinical features, investigations, aetiology, known risk factors, management and outcomes of hospitalised children with AIH.
METHODS
This study was conducted by Public Health England (PHE) and St George's University of London through the British Paediatric Surveillance Unit (BPSU), a unique national clinical surveillance set up to study rare diseases. 3 The BPSU functions by sending paediatric consultants across the UK and Ireland a short electronic list of rare childhood conditions every month. All paediatricians have to respond to the electronic notification and either report a case with a condition in the electronic list (eg, AIH) or confirm that there were no cases to report. Reporting is not compulsory but strongly encouraged, and the BPSU sends monthly reminders, if no response is received. The reporting paediatrician is then requested to complete a questionnaire on demographic, clinical and laboratory information for each case.
This study began on 01 January 2014 for 13 months and included hospitalised children from 1 month up to 14 years of age with raised levels of the liver enzyme, alanine transaminase (ALT), more than twice above the upper limit of normal, with or without jaundice, and any suspicion of an infective cause (with or without an identified causative agent) and excluding drug-induced, metabolic or autoimmune hepatitis. LabBase2, a national electronic reporting system used by National Health Service (NHS) laboratories to notify clinically significant infections to PHE, was used as an alternative national data source for laboratory-confirmed HAV and HBV cases in England, Wales and Northern Ireland. 4 The BPSU does not allow for the request of patient names; so, other parameters such as month and year of birth, gender, NHS number, hospital, diagnosis date and partial postcode were used to crosslink and deduplicate BPSU cases. General practitioners (GPs) were initially contacted to confirm the diagnosis of acute HAV or HBV infection and whether the child was admitted to hospital. After confirmation, the responsible paediatric consultants were also sent the same questionnaire for completion.
Paediatricians who completed the clinical questionnaires for confirmed cases were contacted after 12 months with a follow-up questionnaire on long-term outcomes.
Data analysis
Data were entered into Microsoft Excel and analysed using Stata V.13.0 (Statcorp, Tx). Results are mainly descriptive. Population estimates for 2014 were obtained from the Office for National Statistics for UK and from Central Statistics Office for Ireland and were used to calculate country-specific and overall incidence rates.
Annual age-specific population estimates were adjusted for the 13-month surveillance period. Continuous variables that did not follow a normal distribution were described as medians with IQRs and compared using the Mann-Whitney U test. Categorical data were compared using the χ 2 test or Fisher's exact tests as appropriate. Estimated cases and 95% CIs for HAV/HBV infections in England and Wales were calculated using capture-recapture analysis according to Howitz and colleagues. 5 This methodology is often applied to epidemiological studies to estimate the true number of cases when two or more independent data sources are available for the same population.
RESULTS
Of the 113 notifications received by BPSU during the 13-month surveillance period, 69 cases were included in the study (figure 1); 27 were due to HAV and 3 due to HBV. From England, 55 cases were reported (22 HAV, 4 HBV, 12 others, 18 no aetiology), 12 from Wales, Scotland and Northern Ireland (4 HAV, 0 HBV, 4 others, 4 no aetiology) and 2 from Ireland (1 HAV, 1 no aetiology). During the same period, 268 confirmed hepatitis virus infections among <15-year-olds in England and Wales were reported in LabBase2 (figure 2). The GPs of these children confirmed that the vast majority had mild HAV or known chronic HBV infection, but 12 (10 HAV, 2 HBV) hospitalised cases were identified that had not been notified through the BPSU (figure 2). Including these cases increased the total cohort to 81 children: 37 (45.7%) HAV, 5 (6.2%) HBV, 16 (19.8%) other viruses and 23 (28.4%) with no pathogen identified.
Estimated incidence (n=81)
When analysing BPSU-only cases, AIH incidence across the UK and Ireland was 0.52/100 000 children aged <14 years. In England and Wales, capture-recapture of the 39 HAV/HBV cases (0.38/100 000) identified through BPSU-only (n=17), LabBase2-only (n=12) and both surveillance systems (n=10) estimated the total number of cases to be 1.5-fold higher in 59 (95% CI 40 to 78) cases, with an estimated incidence of acute HAV and HBV in hospitalised children in England and Wales of 0.58/100,000.
HAV cases
Of the 37 children hospitalised with confirmed HAV, 10 were aged <5 years (27.0%), more than two-thirds (26/37, 70.3%) had travelled abroad in the previous 6 months, compared with 2/16 (12.5%) of those infected with other viruses, 1/23 (4.4%) with no aetiology and none of the HBV cases. More than half (18/26, 69.2%) had travelled to countries in the WHO Eastern Mediterranean Region (10 to Pakistan; 3 to Afghanistan; 1 each to Iran, Morocco, Somalia and Yemen), three in the African region (Kenya, Mauritius and Uganda) and four in other regions (Bangladesh, Honduras, Albania and Romania). Only three HAV had received anti-HAV immunisation (8.1%), including two who were vaccinated 1 and 2 weeks prior to becoming unwell, following a case in the family and a school outbreak, respectively. Most presented with gastrointestinal symptoms, and half of them had fever. Bilirubin and ALT levels were significantly raised in nearly all children with HAV infection, while C reactive protein levels were low or normal (see online 
HBV cases
All five UK-born patients with acute HBV infection were previously healthy and were close contacts of known chronically infected individuals (table 2) . Only two were immunised; one neonate received a dose at birth and became unwell before receiving the second dose, while the other patient was lost to follow-up and did not complete the recommended immunisation schedule. The patients with acute HBV infection did not have fever, diarrhoea or rash, but presented with various combinations of abdominal pain, jaundice, lethargy and drowsiness (table 1) . Three were severely unwell at presentation, including two who went on to require a liver transplant.
Other viruses
Other viruses causing AIH included Epstein-Barr Virus (EBV), (n=6), adenovirus (n=4), one case each of CMV, human herpes virus (HHV)6, rotavirus and influenza A H1N1). Two additional cases were positive for EBV coinfection by other viruses (adenovirus, CMV). The patients with AIH caused by other viruses were born in the UK and had not travelled abroad; most of them were previously healthy; one premature twin had been born prematurely and contracted CMV-related hepatitis in the first few weeks of life while still in neonatal intensive care unit, while a young child with neurological malformation developed dual infection with EBV and adenovirus. Proportions were calculated using as denominator the number of participants to the study for the progression in hospital (hepatitis A, 37; hepatitis B, 5; other viruses hepatitis, 16; no viruses hepatitis, 23; total=81), and the number of participants with complete follow-up questionnaires returned for the postdischarge outcome.
More than half presented with jaundice. All patients were managed at their local hospital, had an uneventful course and recovered without complications (table 1). All but one had liver imaging performed and, in five (31.25%), abdominal USS identified inflammatory changes of the liver and perihepatic structures. One also had an MRI scan which showed similar changes to the USS. Two patients (12.50%) had a liver biopsy, which revealed inflammation and hepatonecrosis (see online supplementary table S1). Two patients whose AIH resolved and liver functions returned to normal had complications at follow-up, including one with HHV6 infection who developed acute aplastic anaemia and another with multiple viruses who developed interstitial lung disease.
No aetiology
Children without an identifiable aetiological agent presented mainly with jaundice, fever, vomiting, abdominal pain and lethargy (table 1) . Five children had comorbidities, including sickle cell disease, metastatic malignancy, Charcot-Marie-Tooth, Pierre Robin sequence and Cri-du-chat syndrome. The majority were appropriately investigated and all had an USS, which was normal in 10 (43.48%) and showed hepatomegaly with inflammatory changes in 13 (56.52%) (see online supplementary table S2). Three children (13.04%) had a liver biopsy, which showed inflammation and necrosis of the hepatic parenchyma. One child who initially presented with grade 1 encephalopathy and progressive coagulopathy recovered initially, but then developed Pneumocystis jiroveci pneumonia and died. He was investigated for immunodeficiency, but an underlying cause was not identified. Another boy recovered from AIH and developed enteropathy secondary to enterovirus infection with hypogammaglobulinaemia. All the other children had an uncomplicated course and recovered uneventfully (table 1) .
Outcomes at follow-up
Overall, none of the children-even those with acute HBVdeveloped chronic infection and, apart from the single fatal case, all recovered without long-term complications at 12 months' follow-up.
DISCUSSION
We report the first national prospective study on the epidemiology of AIH in hospitalised children in the UK and Ireland. Our study confirms a low incidence and identified HBV as a rare but severe cause of AIH in hospitalised children. Of the 81 confirmed cases, 37 (46%) had self-limiting HAV infection and 5 had acute HBV infection, with 3 children being very much unwell and 2 needing a liver transplant. A range of other viral infections were confirmed in 20% of children with AIH, while, in 28%, the aetiological agent was not identified despite extensive testing.
In this study, we particularly focused on acute HAV and HBV infections because they are both vaccine-preventable. Although the UK is one of very few countries in the world without a routine HBV vaccination, a very effective antenatal screening programme with high coverage is in place. This programme aims to identify HBV-positive pregnant women and prevent subsequent mother-to-child transmission, and to screen household contacts, and either protect them through immunisation or refer them to specialist care for treatment. Additionally, HBV screening in each pregnancy helps identify mothers with newly acquired HBV infection as well as children infected in previous pregnancies or diagnosed cases that were subsequently lost to follow-up.
In our recent prospective follow-up of children with chronic hepatitis B in England, we identified only three children since 2001, who had become infected through horizontal transmission from household contacts. 6 In the current study, three UK-born children developed acute HBV infection over a 13-month surveillance period, who also acquired the infection from a household contact. These children could potentially have been protected through a routine infant HBV immunisation programme. In all three cases, however, opportunities were missed for screening and vaccinating contacts after an infected individual was diagnosed.
Acute HAV
We identified HAV as the most common cause of AIH in children, acquired mostly after travelling abroad. Follow-up of cases identified through LabBase2 in England and Wales revealed that the majority of children with acute HAV infection were managed in primary care without the need for hospital referral. Of those who were hospitalised, most were admitted for a very short duration, with a median length of stay of 1 day, and recovered without any complications.
Other aetiologies
We also identified other well-known hepatotropic viruses responsible for 20% of AIH cases, especially EBV (8/16, 50%) and adenovirus (5/16, 31%). The only CMV case was a preterm baby with intrauterine growth retardation, who developed AIH while in the neonatal intensive care unit. In one-third of cases, however, the aetiology was not identified. It is reassuring to note that nearly all children in this group were screened for the common hepatitis viruses, and they recovered without sequelae. In severe cases and for cases that do not resolve quickly, early liaison with paediatric specialists may help identify less common causes, such as hepatitis E virus 7 and seronegative hepatitis. 8 
Strengths and limitations
The BPSU provides a unique platform for national surveillance of rare syndromic illnesses with variable or unknown aetiology. Although case ascertainment may not be complete, this methodology has provided a unique insight into the aetiology, clinical course and outcomes of childhood AIH in a country with low HAV/HBV prevalence. A limitation of the study is that we only had an alternative data source for HAV/HBV infections and, therefore, could not ascertain the completeness of AIH due to other viruses or unknown aetiology. Another limitation is the accuracy of the capture-recapture analysis, which assumes a closed population with two independent data sources where individuals have an equal probability of being captured by either source and can be matched adequately. Since paediatricians use the same laboratories for confirming the diagnosis as those that report through LabBase2, the two data sources may not be truly independent; this, however, would underestimate rather than overestimate the total number of HAV/HBV cases.
CONCLUSIONS
Children with AIH generally had good outcomes, except for those with acute HBV infection. Although none went on to develop chronic HBV, one neonate and three children were seriously unwell at presentation, and the latter two went on to require liver transplantation. The UK does not have a universal HBV immunisation programme; a recent economic analysis, however, indicated that infant HBV immunisation could be costeffective if the vaccine could be procured at a low price, ideally as part of a multivalent combination vaccine. The infant HBV vaccination programme would have to be in addition to the current antenatal screening programme and could potentially reduce both acute and chronic HBV cases acquired through horizontal transmission, but would not prevent cases in children born abroad. Like HIV or other serious chronic illnesses, clinicians should liaise early with paediatric specialists to ensure children with acute and chronic HBV infections receive the best possible specialist care and follow-up.
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